Vertex’s Strategic Acquisition of Alpine Immune Sciences Signals Major Immunology Push

At the recent Wells Fargo Healthcare Conference, Vertex Pharmaceuticals CEO Reshma Kewalramani underscored the profound strategic importance of the company’s multi-billion dollar acquisition of Alpine Immune Sciences. This move represents a significant commitment to expanding Vertex’s immunology portfolio.

Finalized in the second quarter of 2024 after being announced in April of the same year, the transaction saw Vertex paying $65 per share, culminating in a total deal value of approximately $4.9 billion. Following the successful completion of the tender offer, Alpine Immune Sciences shares were delisted. The centerpiece of this acquisition is the promising drug candidate Povetacicept (formerly ALPN-303), a dual BAFF/APRIL antagonist. Clinical data has been compelling; in Phase 1b/2a studies, the treatment demonstrated a 64.1% reduction in Read more...